Evaluation of care pathways for obese patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the care pathway provided by the Chronic Disease Unit to patients suffering from obesity. It involves an initial consultation where patients complete various questionnaires assessing their quality of life, self-efficacy, and psychological well-being. Follow-up visits at 3 and 6 months will include additional assessments and a satisfaction questionnaire. The study aims to enhance patient education and support in managing obesity effectively.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient identified by the network or referred by a healthcare professional,
2. Patient aged 18 or over,
3. Patient suffering from obesity defined by a BMI ≥ 30,
4. Patient who understands and speaks French.

Exclusion Criteria:

1. Opposition of the patient to participation in the study,
2. Pregnant, parturient or breast-feeding woman,
3. Patient undergoing bariatric surgery,
4. Patient under judicial protection (guardianship, curatorship, etc.) or safeguard of justice,
5. Patients with unstable psychiatric disorders,
6. Patients on neuroleptics,
7. Any other reason which in the opinion of the investigator, could interfere with the evaluation of the study objectives.

Where it's running

• Mmc
  La Garde, Var, France Recruiting

Study contacts

• Study coordinator: Sophie LAFOND
• Email: sophie.lafond@ch-toulon.fr
• Phone: 04 83 77 20 62

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.